Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET
Company Participants
Avi Oler - Senior Vice President-Corporate Development and General Counsel
Steve Fruchtman - President and Chief Executive Officer
Mark Gelder - Chief Medical Officer
Mark Guerin - Chief Financial Officer
Conference Call Participants
Charles Zhu - Guggenheim
Ahu Demir - Ladenburg
Joe Pantginis - H.C. Wainright
Robert LeBoyer - Noble Capital Markets
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics' First Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared [Technical Difficulty] [Operator Instructions] As a reminder, this call is being recorded today, May 11,022.
At this time, I'd like to turn the call over to Avi Oler, Senior Vice President of Corporate Development and General Counsel.
Avi Oler
Thank you operator, and welcome everyone to Onconova's first quarter 2022 financial results and business update conference call. Earlier this afternoon, we issued a press release reporting our financial results and business progress. If you have not yet seen this press release, it is available on the Investors and Media section of our website at www.onconova.com.
Today's call will begin with our President and CEO, Dr. Steve Fruchtman providing an overview of our recent progress and corporate strategy. Dr. Fruchtman will then ask our Chief Medical Officer, Dr. Mark Gelder to review our clinical programs. Our CFO, Mark Guerin will then report our first quarter financial results before we move on to a question-and-answer session.
Before turning the call over to Steve, I’d like to remind everyone that statements made by management during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in today’s press release and the risk factors in the company’s SEC filings.
With that, it is my pleasure to turn the call over to Steve.
Steve Fruchtman
Thank you, Avi and good afternoon everyone. Our clinical programs continued to make strong progress over the past months as we efficiently executed on the corporate strategy we've spoken about on our past earnings calls. This strategy has us internally focused on our nerazacyclib program, while leveraging relationships with thought leaders from industry and academia to continue the development of rigosertib through investigator-sponsored studies, based on the mechanism of action of rigosertib to target cancer indications of interest.